ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors.

HAL Id: inserm-00143967

https://www.hal.inserm.fr/inserm-00143967

Submitted on 30 Apr 2007

HAL is a multi-disciplinary open access

archive for the deposit and dissemination of sci-entific research documents, whether they are pub-lished or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

activity are differentially regulated by HDAC inhibitors.

Vanessa Duong, Anne Licznar, Raphaël Margueron, Nathalie Boulle, Muriel

Busson, Matthieu Lacroix, Benita Katzenellenbogen, Vincent Cavaillès,

Gwendal Lazennec

To cite this version:

Vanessa Duong, Anne Licznar, Raphaël Margueron, Nathalie Boulle, Muriel Busson, et al.. ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors.. Oncogene, Nature Publishing Group, 2006, 25 (12), pp.1799-806. �10.1038/sj.onc.1209102�. �inserm-00143967�

C TSA

Protein

ERβ −

C TSA Protein ERα −

C

0 20 40 60 80 100

C

TSA CHX CHX

+TSA

0 100 200 300 400

ER

α

mRNA

levels

(% of control)

C

TSA CHX CHX

+TSA

ER

β

mRNA

levels

(% of control)

0 200 400 600

ER

β

mRNA

levels

(% of control)

C TSA

HeLa MDA-MB-231 0 200 400 600 800 1000 1200 0 1000 2000 3000 4000 PEO14 HEK293 0 1000 2000 3000 4000 0 200 400 600 800 C T S A S A H A

ERα

ERβ

N a B u 0 200 400 600 800 1000 1200 1400 1600 1800 Control E2 HDI E2+HDI C TS_A SA_H A N a B u

B

Duong et al.

Fig. 2

0 50 100 150 200 250 300 350 400 450

CMV5

ERα

ERβ

Control E2 HDI E2+HDI pS2 promoter

C

RLU

RLU

RLU

CMV5

ERα

ERβ

CMV5

ERα

ERβ

CMV5

ERα

ERβ

CMV5

ERα

ERβ

Control E2 HDI E2+HDI

B

Control

RLU

-12 -11 -10 -8 -6 Log E2 concentration (M) -7 -9

C

-12 -11 -10 -8 -6 Log E2 concentration (M) -7 -9

RLU

1000 1200 2000 control E2 OHTam ICI 0 50 100 150 200 250 300 350 400 450 500 1000 1500 2000 2500 0 0 500 1000 1500 2000 control PPT DPN CMV TSA C ERα TSA C ERβ TSA C

RLU

TSA

B

Relative Luciferase Activity

A/B

C D

E

F

C D

E

F

WT WT ΔAB

Duong et al.

Fig. 4

0 100 200 300 400 500

CMV5

WT

ΔA/B

WT

ΔA/B

0 500 1000 1500 2000

hER

α

hER

β

C TSA E2 E2 + TSA

hER

α

hER

β

CMV5

WT

ΔA/B

WT

ΔA/B

Ad5

Ad-hERα

Ad-hERβ

0 20 40 60 80 100 120

Proliferati

o

n

(% of

control)

800 1000 C TSA

B

C

Ad5

Ad-hERα

Ad-hERβ

Proliferati

o

n

(% of

control)

C TSA 0 20 40 60 80 100 C TSA

- Cyclin E

C TSA C TSA

ERα

ERβ

- p21

C TSA C TSA

ERα

ERβ

B

ERα

ERβ

0 20 40 60 80 100

RLU

C

Duong et al.

Fig. 6

RLU

0 100 200 300 400 500 600

ERα

ERβ

0 500 1000 1500 2000

ERα

ERβ

RLU

Cyclin E

0 200 400 600 800 1000 1200

AP1

RLU

ERα

ERβ